Marianna Arsenovna Zolotovskaya, Researcher, Laboratory of Translational and Genomic Bioinformatics, Moscow Institute of Physics and Technology. An experienced bioinformatician, at the same time a certified oncologist. She was the first to develop a method for quantifying the effect of the total mass of mutations in protein-coding genes on the functioning of molecular pathways (Zolotovskaia et al., Front Oncol. 2019 Jan 4;8:658). Created a method for screening genes-potential molecular targets of anticancer drugs, based on the quantitative assessment of involvement in various molecular processes inside the cell (Zolotovskaia et al., Front Pharmacol. 2019 Jan 23;10:1; Zolotovskaia et al., Methods Mol Biol. 2020; 2063:207-234). First investigated the profiles of genetic and transcriptome changes for 419 molecular pathways on a wide sample (about 5000) of clinically annotated transcription and mutation data (Zolotovskaia et al., Cancers (Basel). 2020 Jan 22;12(2)). Based on the analysis of genetic and expression heterogeneity, she was the first to compare the profiles of clinically recommended targeted drugs and the molecular features of tumors.